Marlborough

Business growth in MetroWest is continuing the same measured pace in 2015 that the annual Business Climate Survey found last year, with companies expecting moderate growth in jobs and revenue throughout this year.

Boston Scientific of Marlborough has received Food and Drug Administration approval for its Innova stent system for treatment of patients with peripheral artery disease.

Marlborough-based Ocata Therapeutics has secured up to $10 million in financing to push toward commercialization of a drug to treat forms of macular degeneration, the company announced Wednesday.

Central Massachusetts, especially Worcester, is home to a number of nonprofits and other tax-exempt organizations. Last year, more than 30 percent of all land in the city was tax exempt.

More than 14,000 Massachusetts residents have received checks for $205.52 each from Fidelity Bank of Fitchburg as part of a relief fund settlement reached last year with the state, Secretary of the Commonwealth William F. Galvin announced Friday.

RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, has cut second quarter losses and secured an additional year of cash as it continues to advance its clinical and preclinical pipeline.

The residential solar company Sunrun, based in San Francisco, has announced that it will open a new branch office in Marlborough, bringing more than 100 jobs to the area.

Life sciences firm Ocata Therapeutics of Marlborough, working toward commercialization of a drug to treat a form of macular degeneration, substantially lowered its net loss for the second quarter, the company announced Thursday.

Despite a slower than expected quarter, ReWalk Robotics of Marlborough saw a revenue jump of more than 20 percent, but declared a $5.8 million loss as the manufacturer of robotic exoskeletons for spinal cord-injury victims seeks more customers.

Oxford Immunotec, a diagnostics company with U.S. headquarters in Marlborough, announced revenue growth in the second quarter of 2015 alongside continued overall losses.